Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 5/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.44 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 3/20 | 0.44 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12015142 | 1.00 | HINT1 (0.51) | HINT1NT5EHPGDTGM2TAS1R3 | |
| SCHEMBL12590077 | 1.00 | HINT1 (0.51) | HINT1NT5EHPGDTGM2TAS1R3 | |
| SCHEMBL18058951 | 0.93 | HINT1 (0.49) | HINT1NT5EHPGDTGM2TAS1R3 | |
| SCHEMBL12087507 | 0.92 | NT5E (0.50) | HINT1NT5EHPGDTGM2TAS1R3 | |
| SCHEMBL12590117 | 0.92 | NT5E (0.50) | HINT1NT5EHPGDTGM2TAS1R3 | |
| SCHEMBL12015195 | 0.92 | NT5E (0.50) | HINT1NT5EHPGDTGM2TAS1R3 | |
| SCHEMBL12590130 | 0.91 | HINT1 (0.57) | HINT1NT5EHPGDTGM2TAS1R3 | |
| SCHEMBL12015199 | 0.91 | HINT1 (0.57) | HINT1NT5EHPGDTGM2TAS1R3 | |
| SCHEMBL12087514 | 0.91 | HINT1 (0.57) | HINT1NT5EHPGDTGM2TAS1R3 | |
| SCHEMBL12590073 | 0.90 | NT5E (0.53) | HINT1NT5EHPGDTGM2TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998108-A1 | ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 PRE-MRNA | Daiichi Sankyo Company, Limited (JP) | 2022-05-18 | — | — | EP | disclosed |
| WO-2019172286-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | 第一三共株式会社 | 2019-09-12 | — | — | WO | disclosed |
| EP-2647713-B1 | MODIFIED SINGLE-STRAND POLYNUCLEOTIDE | DAIICHI SANKYO CO LTD (JP) | 2018-02-21 | — | — | EP | disclosed |
| US-9885036-B2 | Double-stranded polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| US-9657050-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | Masafumi, Matsuo (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9657049-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | Matsuo, Masafumi (JP) | 2017-05-23 | — | — | US | disclosed |
| EP-2530153-A1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-2530155-A1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-2530154-A1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-2530156-A1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-2495323-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | Daiichi Sankyo Company, Limited (JP) | 2012-09-05 | — | — | EP | disclosed |
| EP-2392660-A2 | ENA Nucleic Acid Drugs Modifying Splicing in mRNA Precursor | Matsuo, Masafumi (JP) | 2011-12-07 | — | — | EP | disclosed |
| EP-2386636-A2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2011-11-16 | — | — | EP | disclosed |
| EP-2374885-A2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED | 2011-06-23 | — | — | US | disclosed |
| EP-2305805-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | Daiichi Sankyo Company, Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7902160-B2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20110046360-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | Matsuo, Masafumi (JP) | 2011-02-24 | — | — | US | disclosed |
| EP-2135948-A2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2009-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | NSUN2, TRDMT1, POLRMT | HINT1 2069/4885NT5E 266/4885HPGD 4708/4885 |
| US-20110046360-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | SNRPA, RBM17, SNRPA1 | HINT1 2656/4885NT5E 155/4885HPGD 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.